Hiroyuki Tsunemori

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet · 2017 · 177 citations · Full text

Medicine, Oncology, Pharmacology +15

Expression of Autotaxin and Acylglycerol kinase in prostate cancer: Association with cancer development and progression

Mohammed Nouh, Xiu‐Xian Wu, Homare Okazoe et al. · Cancer Science · 2009 · 95 citations · Full text

Medicine, Cancer Biology, Oncology +17

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet Oncology · 2019 · 85 citations · Full text

Medicine, Oncology, Pharmacology +16

EXPRESSION OF A NOVEL BIOMARKER, EPCA, IN ADENOCARCINOMAS AND PRECANCEROUS LESIONS IN THE PROSTATE

Hirotsugu Uetsuki, Hiroyuki Tsunemori, Rikiya Taoka et al. · The Journal of Urology · 2005 · 76 citations

Medicine, Oncology, Pathology +17